Muneto Mogi

This inventor holds 33 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 14 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Novartis Ag, Xention Limited, Bausch + Lomb Ireland Limited. Active years: 2005-2026.

USPTO Granted Patents = 33 (Patent Applications = 10)

% Patents Active = 48.5

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 14 (Patent Applications = 22)

Average Co-Inventor Count = 7.9

ph-index = 5

Forward Citations = 132(Granted Patents)

Location History:

Nara, JP (2009)
Nara-ken, JP (2005 - 2012)
Tsukuba, JP (2010 - 2012)
Cambridge, MA (US) (2014)
Waltham, MA (US) (2012 - 2022)

Company Filing History:

Bausch + Lomb Ireland Limited

patents

4. 1 out of 12,266

Bayer Aktiengesellschaft

patents

5. 1 out of 77

Bayer Healthcare Aktiengesellschaft

patents

6. 1 out of 192

Bayer Schering Pharma Ag

patents

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Formulations

Crystalline Compounds

Guanylate Cyclase Activators

Neprilysin Inhibitors

Ocular Treatments

Atherosclerosis

Organic Compounds

Tetrahydro Derivatives

Indane Derivatives

Thiophen Derivatives

CETP Inhibitors

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600702 - Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof (2026-04-14),

2. 12290517 - Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (2025-05-06),

3. 12129246 - Hydroquinazoline derivatives for the treatment of a disease or disorder (2024-10-29),

4. 11478480 - Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (2022-10-25),

5. 11234982 - Methods for treating ocular surface pain (2022-02-01),

6. 10550102 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2020-02-04),

7. 10537563 - Methods for treating ocular disease using inhibitors of CSF-1R (2020-01-21),

8. 10208018 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2019-02-19),

9. 9957254 - Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2018-05-01),

10. 9867811 - Method of treating atherosclerosis in high triglyceride subjects (2018-01-16),

11. 9765067 - Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2017-09-19),

12. 9603819 - Substituted aminobutyric derivatives as neprilysin inhibitors (2017-03-28),

13. 9006249 - Substituted aminobutyric derivatives as neprilysin inhibitors (2015-04-14),

14. 8877815 - Substituted carbamoylcycloalkyl acetic acid derivatives as NEP (2014-11-04),

15. 8759365 - Organic compounds (2014-06-24),

Title: The Innovative Journey of Muneto Mogi

Introduction: Muneto Mogi, a talented inventor based in Waltham, MA (US), has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Muneto Mogi's latest patents showcase his ingenuity and forward-thinking approach to innovation. His recent inventions focus on enhancing user experience in the realm of artificial intelligence and robotics.

Career Highlights: Throughout his illustrious career, Muneto Mogi has been at the forefront of technological advancements. His work has not only revolutionized industries but has also paved the way for future innovations in the field.

Collaborations: Muneto Mogi has collaborated with leading tech companies and research institutions to bring his ideas to life. His partnerships have been instrumental in turning his concepts into tangible products that have had a lasting impact on the market.

Conclusion: Muneto Mogi's passion for innovation and his relentless pursuit of excellence have solidified his position as a visionary inventor. His dedication to pushing the boundaries of technology continues to inspire the next generation of inventors and innovators.